This company has been acquired
Axonics (AXNX) Stock Overview
A medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AXNX from our risk checks.
AXNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Axonics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$70.98 |
| 52 Week High | US$71.05 |
| 52 Week Low | US$55.09 |
| Beta | 0.83 |
| 1 Month Change | 1.00% |
| 3 Month Change | 3.12% |
| 1 Year Change | 24.48% |
| 3 Year Change | 18.12% |
| 5 Year Change | 220.89% |
| Change since IPO | 373.83% |
Recent News & Updates
Recent updates
Axonics' Market Growth Strengthens Boston Scientific's Future
Nov 05A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)
Jul 14
Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors
Jun 20Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?
Mar 27Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation
Feb 28Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?
Nov 28Axonics stock falls 5.6% after Needham downgrades rating
Oct 10Axonics Stock Is A Buy Amid Current Capex Cycle
Sep 07Axonics prices stock offering of 1.75M shares
Aug 03Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth
Aug 02Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities
May 30Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business
Apr 19Shareholder Returns
| AXNX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.8% | 1.6% | 1.1% |
| 1Y | 24.5% | -0.7% | 16.7% |
Return vs Industry: AXNX matched the US Medical Equipment industry which returned 25.2% over the past year.
Return vs Market: AXNX underperformed the US Market which returned 33.1% over the past year.
Price Volatility
| AXNX volatility | |
|---|---|
| AXNX Average Weekly Movement | 0.5% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AXNX's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 797 | Ray Cohen | www.axonics.com |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.
Axonics, Inc. Fundamentals Summary
| AXNX fundamental statistics | |
|---|---|
| Market cap | US$3.60b |
| Earnings (TTM) | -US$5.66m |
| Revenue (TTM) | US$431.90m |
Is AXNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXNX income statement (TTM) | |
|---|---|
| Revenue | US$431.90m |
| Cost of Revenue | US$101.10m |
| Gross Profit | US$330.81m |
| Other Expenses | US$336.47m |
| Earnings | -US$5.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 76.59% |
| Net Profit Margin | -1.31% |
| Debt/Equity Ratio | 0% |
How did AXNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/14 05:50 |
| End of Day Share Price | 2024/11/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axonics, Inc. is covered by 7 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | Barclays |
| Travis Steed | BofA Global Research |
| Christopher Pasquale | Guggenheim Securities, LLC |